Seeing Is Believing

Currently out of the existing stock ratings of Steve Chesney, 20 are a BUY (41.67%), 6 are a SELL (12.5%), 22 are a HOLD (45.83%).
Analyst Steve Chesney, currently employed at REDBURN, carries an average stock price target met ratio of 70.42% that have a potential upside of 25.97% achieved within 484 days.
Steve Chesney’s has documented 94 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BMY, Bristol-Myers Squibb Company at 05-Feb-2024.
Analyst best performing recommendations are on CELG (CELGENE).
The best stock recommendation documented was for CELG (CELGENE) at 12/18/2015. The price target of $122 was fulfilled within 5 days with a profit of $11.86 (10.77%) receiving and performance score of 21.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$149
$-0.89 (-0.59%)
$152
16 days ago
(09-Oct-2025)
24/47 (51.06%)
$2.43 (1.66%)
266
Hold
1 months 2 days ago
(23-Sep-2025)
7/32 (21.88%)
$112.06 (70.95%)
255
Hold
$118
$-31.89 (-21.28%)
$115
2 months 12 days ago
(13-Aug-2025)
0/2 (0%)
$-16.94 (-12.55%)
Buy
$213
$63.11 (42.10%)
$205
3 months 29 days ago
(26-Jun-2025)
39/69 (56.52%)
$86.92 (68.94%)
121
Buy
$187
$37.11 (24.76%)
$187
4 months ago
(25-Jun-2025)
9/23 (39.13%)
$60.08 (47.34%)
260
What Year was the first public recommendation made by Steve Chesney?